SOUTH SAN FRANCISCO, Calif., July 25, 2025 – Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company developing CAR T-cell therapies, today announced a private placement agreement expected to raise up to $100 million in gross proceeds from institutional and accredited investors.
The initial funding tranche is set to close today, July 25, 2025. The financing also includes two potential future tranches, each for additional funding: a “Milestone Closing” at Lyell’s option upon achieving clinical or corporate milestones within 12 months, and an “Investor Call Closing” at the investor’s option before the Milestone Closing. To manage ownership thresholds, investors purchasing above a certain percentage will receive pre-funded warrants.
Lyell plans to use the net proceeds, combined with existing capital, to fund two pivotal-stage clinical trials for LYL314 and for general corporate purposes. This financing is expected to extend Lyell’s cash runway into mid-2027, supporting key milestones including data from the LYL314 PiNACLE trial, a BLA submission in late 2027, a Phase 3 trial for LYL314, and a new CAR T-cell therapy trial for solid tumors.
This private placement is unregistered under the Securities Act of 1933, and securities are subject to resale restrictions. Investors have been granted customary resale Form S-3 registration rights.
This press release is for informational purposes only and does not constitute an offer to sell or a solicitation to buy securities.
Source:
https://endpoints.news/circular-rna-startup-orbital-unveils-first-monkey-data-as-it-enters-in-vivo-car-t-cell-therapy-race/?utm_source=dlvr.it&utm_medium=linkedin
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
